Indications
Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
Composition
- Active substance
- daridorexant hydrochloride
- International name (INN)
- daridorexant
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Quviviq
- Active substance
- daridorexant hydrochloride
- ATC code
- N05CJ03
- Group
- Nervous system
- Therapeutic area
- Sleep Initiation and Maintenance Disorders
- Marketing authorisation holder
- Idorsia Pharmaceuticals Deutschland GmbH